Authors : Shinsuke Sato , Takeo Maekawa , Koichi Sato , Hiroshi Maekawa , Kazutomo Ouchi , Mutsumi Sakurada , Tomoyuki Kushida , Motomi Nasu , Akira Tsukada and Yuji Sugiyama
Abstract: Sivelestat sodium hydrate (Elaspol�, Ono Pharmaceutical Co., Osaka, Japan) is a new elastase inhibitor for treating Acute Lung Injury (ALI). We studied the efficacy of sivelestat in treating postoperative ALI and compared its effectiveness between two groups of patients. The subjects were 11 patients who had undergone surgery at our hospital and received sivelestat for 5 days or longer to treat postoperative ALI. These patients were divided into a sivelestat-effective group and a sivelestat-ineffective group according to the PaO2/FiO2 ratio and lung injury score on the sixth day after the start of treatment. The Sequential Organ Failure Assessment (SOFA) scores, number of damaged organs, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores and C-reactive protein levels were examined in each group. Six patients were classified as the effective group and 5 patients as the ineffective group. The APACHE II score was significantly higher in the ineffective group after the second day of treatment with sivelestat and remained significantly higher until the sixth day of treatment. Our results suggest that the effects of sivelestat on postoperative ALI can be predicted through use of the APACHE II score in the early period after surgery.
Shinsuke Sato , Takeo Maekawa , Koichi Sato , Hiroshi Maekawa , Kazutomo Ouchi , Mutsumi Sakurada , Tomoyuki Kushida , Motomi Nasu , Akira Tsukada and Yuji Sugiyama , 2007. Clinical Evaluation to Predict Effectiveness of Sivelestat Sodium Hydrate for Postoperative Acute Lung Injury by APACHE II Score. Surgery Journal, 2: 14-18.